Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder associated with allergic hypersensitivity to food. We interrogated >1.5 million genetic variants in EoE cases of European ancestry and subsequently in a multi-site cohort with local and out-of-study control subjects. In addition to replicating association of the 5q22 locus (meta-analysis P = 1.9 × 10 −16 ), we identified an association at 2p23 spanning CAPN14 (P = 2.5 × 10 −10 ). CAPN14 was specifically expressed in the esophagus, was dynamically upregulated as a function of disease activity and genetic haplotype and after exposure of epithelial cells to interleukin (IL)-13, and was located in an epigenetic hotspot modified by IL-13. Genes neighboring the top 208 EoE-associated sequence variants were enriched for esophageal expression, and multiple loci for allergic sensitization were associated with EoE susceptibility (4.8 × 10 −2 < P < 5
l e t t e r s 2 ). This series of consistency checks was used to reduce the chance of identifying false positives due to the inclusion of an external control cohort.
Markers at 2p23, 5q22, 8p23 and 15q13 had associations that reached genome-wide significance (P < 5 × 10 −8 ). The variants most highly associated with increased risk of EoE were found at 2p23 spanning the CAPN14 gene (best SNP rs77569859, P = 3.30 × 10 −10 , odds ratio (OR) = 1.98) ( Table 1) . To identify commonly occurring variants (minor allele frequency (MAF) > 1%) on the risk haplotype that could be driving the genetic association, we imputed this region to a composite reference panel from the 1000 Genomes Project 17, 18 ; no haplotype of continuous SNPs or haplotype constructed using the most associated variants in the region was more highly associated with EoE risk than rs77569859 alone (best haplotype P = 3.5 × 10 −8 , OR = 1.6; Fig. 1b and data not shown). Variants at the other two newly discovered loci reaching genome-wide significance were located in the XKR6 (encoding XK, Kell blood group complex subunit-related Figure 1 Manhattan plot of the P values obtained from the genome-wide association analysis. (a) Data are from 736 subjects with EoE and 9,246 controls over 1,468,075 genetic variants with MAFs greater than 1% in the subjects with EoE. The −log 10 value of each probability is shown as a function of genomic position on the autosomes. Genome-wide significance (red dashed line; P ≤ 5 × 10 −8 ) and suggestive significance (solid blue line; P ≤ 1 × 10 −7 ) are indicated. (b-e) Genetic association of variants at the 2p23 (b), 5q22 (c), 8p23 (d) and 15q13 (e) loci with EoE risk. P values (−log 10 ) from the genetic association analysis of genotyped and imputed variants are plotted against the genomic position of each genotyped (blue) and imputed (red) SNP on the x axis on chromosomes 2, 5, 8 and 15. Genes in the region are shown above. Black lines indicate the recombination rates determined using subjects of European ancestry from the 1000 Genomes Project. Loci included in this table had significant or suggestive associations (P < 5 × 10 −6 ) and were consistently associated in the CCHMC cohort (P < 0.0005), local analysis (P < 0.05) and CoFAR cohort (P < 0.05). Data for those loci that failed one of these consistency checks can be found in supplementary npg l e t t e r s family, member 6) gene (8p23) and in a gene desert (15q13). Very little is known about XKR6; however, public expression databases report its expression in the immune compartment (Supplementary Fig. 2 ). These four genome-wide susceptibility loci remained associated with EoE, and their effect sizes were not significantly influenced by correction for atopy (Supplementary Table 3 ).
Using an independently ascertained cohort that did not overlap with the first EoE GWAS 9 , we observed strong replication of disease association at 5q22 (rs6594499, Fisher's combined P = 1.9 × 10 −16 ; Supplementary Table 4) . After imputation of the region, the most significant association with the development of EoE was downstream of TSLP and WDR36 at rs1438672 (Fig. 1c) , with 12 variants having association P < 1 × 10 −2 (P values between 0.001 and 0.05) after adjusting for the most significant variant. After accounting for multiple testing, we cannot reject the null hypothesis that there is one independent genetic effect at this locus.
Variants at 1p13, 5q23, 10p12, 11q13, 11q14 and 21q22 demonstrated suggestive genetic association with EoE (P < 1 × 10 −7 ) (Fig. 1,  Table 1 and Supplementary Figs. 3 and 4) . After establishing statistical associations between genetic variants at these loci and EoE, we npg l e t t e r s performed fine-mapping studies starting with imputation of variants not captured in the combined GWAS data set ( Fig. 1 and Supplementary  Fig. 3 ). The 11q13 region has been associated with asthma 19, 20 , atopic dermatitis [21] [22] [23] [24] , inflammatory bowel disease 25 , allergic rhinitis 26 and sensitization to grass 26 . The EoE-associated variants at 11q13 were located between C11orf30 (encoding chromosome 11 open reading frame 30) and LRRC32 (encoding leucine-rich repeat-containing 32, also known as GARP). LRRC32 has a role in latent transforming growth factor (TGF)-β surface expression 27 , and LRRC32 mRNA is highly expressed in activated forkhead box P3 (FOXP3)-positive T regulatory cells. Notably, TGF-β and FOXP3 + T regulatory cells have been implicated in EoE [28] [29] [30] [31] [32] . CAPN14 encodes calpain 14, a calcium-activated cysteine protease. A survey of 130 tissues showed that CAPN14 was most highly expressed in the esophagus ( Fig. 2a and Supplementary Fig. 5 ). When we assessed the expression of calpain family members in biopsies from subjects with and without EoE, we found distinct patterns for control subjects, those treated for EoE and those with uncontrolled (active) EoE. Notably, CAPN14 was dynamically expressed as a function of disease activity (Fig. 2b) . CAPN14 showed the greatest upregulation in comparison to all members of the CAPN family (Fig. 2b) , but the expression of 3 of the other 15 family members-CAPN3, CAPN5 and CAST (encoding calpastatin)-was also dysregulated in EoE esophageal biopsies (Fig. 2b) . CAST encodes a calpain inhibitor and was downregulated (29%; P < 1 × 10 −4 ). We found a >2-fold increase in CAPN14 levels in the esophageal biopsies of individuals with active EoE (Fig. 2c) . Furthermore, IL-13 stimulation of primary esophageal epithelial cells and an esophageal epithelial cell line grown at the air-liquid interface (ALI) with IL-13 ( Fig. 2f) resulted in a 4-fold and >100-fold increase in CAPN14 levels, respectively (Fig. 2d,g ). Individuals with the risk haplotype expressed 30% lower CAPN14 mRNA levels than those without the risk haplotype (P < 1 × 10 −2 ) (Fig. 2e) .
To identify the genomic mechanisms that might underlie the association at 2p23 with EoE, we performed chromatin immunoprecipitation sequencing (ChIP-seq) on esophageal epithelial cells stimulated with IL-13. Of the six SNPs most highly associated at the CAPN14 locus after imputation, two (rs76562819 and rs75960361) were located in putative regulatory regions, according to IL-13-induced acetylation of histone H3 at lysine 27 (H3K27ac) in ChIP-seq data for esophageal epithelial cells, as well as publically available Encyclopedia of DNA Elements (ENCODE) functional genomics data (including histone marks, DNase I hypersensitivity data and ChIP-seq data) [33] [34] [35] (Fig. 2h) .
rs76562819 is located proximal to the 5′ end of the CAPN14 transcription start site (Fig. 2h) , lies within a region of elevated monomethylation of histone H3 at lysine 4 (H3K4me1) in multiple cell lines and intersects with open chromatin regions in 34 cell types, according to DNase I hypersensitivity site mapping data. We subsequently performed an electrophoretic mobility shift assay (EMSA) using a capture probe from this region and found that the risk allele (rs7462819) preferentially bound to a nuclear protein complex in comparison to the non-risk allele (Fig. 2i) .
Notably, CAPN14 was the only CAPN family member whose expression was upregulated, as measured by microarray and RNA sequencing (RNA-seq), in either primary epithelial cells from esophageal biopsies or organotypic cultures after stimulation with IL-13 (Fig. 3a) , consistent with previous findings in other cell types 36, 37 . IL-13 increased calpain activity in esophageal epithelial cells stimulated with IL-13, and this activity was inhibited by a calpain-specific inhibitor (Fig. 3b) .
We searched for proximal (cis-acting) expression quantitative trait loci (eQTLs) using gene expression data obtained from six cell types or tissues (white blood cells, lymphoblastoid cell lines, whole blood, adipose tissue, B cells and monocytes). At two of the ten most highly associated EoE risk loci, the sentinel SNP was associated (P < 1 × 10 −3 ) with the expression of one or more nearby genes. Specifically, the most highly associated variants at 1p13 and 8p23 were strongly associated with the expression of the nearest genes, SLC25A24 (encoding solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 24; P = 1.25 × 10 −9 ) and XKR6 (P = 1.02 × 10 −7 ) (Supplementary Table 5 ). Using our own expression databases, we have previously reported that TSLP expression is upregulated in biopsies from individuals with EoE in an allele-dependent manner and in esophageal epithelial cell lines treated with polyinosinic:polycytidylic acid 9, 10 .
We measured the expression in RNA-seq data of all genes within 25 kb of variants with combined association P < 1 × 10 −4 . Of these 208 genes, 48% were expressed in the esophagus at appreciable levels 38 ; this proportion represents an enrichment relative to the expression of the whole genome in the esophagus (P < 1 × 10 −4 , permutation testing). Furthermore, differential expression of these genes was sufficient to segregate EoE cases from controls, and 8% of the genes near the most highly associated EoE risk loci were differentially expressed (>2-fold average change, Bonferroni-adjusted P < 5 × 10 −2 ) in EoE case CAPN14  RARB  BTN3A3  UBA7  CCDC51  CD44  IFFO2  TCF4  CLDN23  SIGLEC10  AMPD3  TMEM194A  THBD  IMPA2  CAPN5  SCNN1B  TIMP2 Figure 4 Genes at EoE risk loci with differential expression in biopsies from EoE cases relative to controls. Genes within 25 kb of the 768 genetic variants associated with EoE (combined P < 1 × 10 −4 ) were used in this analysis of RNA-seq data. The expression of 208 genes was assessed. Normalized fold change in expression is shown for all genes with at least twofold average change and corrected P < 0.05. NL, normal controls.
l e t t e r s and control biopsies (Fig. 4 and Supplementary Fig. 6 ). Therefore, these data demonstrate a concentration of EoE susceptibility loci in the neighborhood of genes that are expressed and/or dysregulated in the esophagus of diseased individuals, suggesting an esophageal functional role for the implicated genes. We assessed the GWAS associations for differential H3K27ac marks in epithelial cells after IL-13 stimulation. Notably, CAPN14 was one of two genes with these IL-13-responsive epigenetic characteristics (Supplementary Fig. 7 ). This analysis further underscores the potential centrality of CAPN14 in the etiology of EoE. These data are consistent with the mechanistic model in which CAPN14 is dynamically expressed in the esophagus in response to inflammatory stimuli, a regulatory mechanism that is disrupted by the decreased expression associated with the risk haplotype (Supplementary Fig. 8 ).
The previous genome-wide study of EoE did not assess the most significant variant in CAPN14 but did identify suggestive association (P < 1 × 10 −4 ) from variants in the region 9 . With additional EoE cases and controls, the current study was better powered to identify statistically significant association of genetic variants with the development of EoE. A limitation of this study is the lack of a replication stage for those loci that were most highly associated with EoE in the combined analysis of the two independent cohorts that were assessed. As such, apart from the associations at TSLP-WDR36 and CAPN14, the highly associated loci remain suggestive until confirmed in subsequent studies.
Two recent GWAS reported 22 loci associated with allergic sensitization 39, 40 . Notably, we found association with EoE at 9 of these 22 loci (Supplementary Table 6) , underscoring the key role of atopy in EoE, and 8 of these SNPs were associated with comparable effects on disease risk. The atopic sensitization loci with the greatest association with EoE were located in CLEC16A (encoding C-type lectin domain family 16, member A), LRRC32 (encoding leucine-rich repeat-containing 32), LPP (encoding LIM domain-containing preferred translocation partner in lipoma) and TSLP-WDR36 ( Fig. 1 and  Supplementary Fig. 9 ). However, of the 10 loci that were associated with EoE in our study, only 2 overlapped with the 22 allergic sensitization loci, highlighting the possibility that non-atopy-related processes might be operational in EoE.
In conclusion, herein we have increased the number of putative susceptibility loci for EoE from one to four and present compelling evidence for six other loci. Notably, our data substantiate a mechanism to elucidate the tissue-specific manifestations of this prototypic allergic disease. In particular, we provide additional evidence of shared genetic and molecular pathways in general atopy risk factors (for example, TSLP-WDR36, LRRC32, IL33 and LPP) and EoE diseasespecific elements, most notably genetic risk factors present at 2p23 where CAPN14 is located. Consistent with this model, the CAPN14 gene is located in a baseline epigenetic hotspot that is modified by IL-13, and CAPN14 is specifically expressed in esophageal epithelium and is dynamically upregulated as a function of disease activity and genetic haplotype and after exposure of epithelial cells to IL-13. We further note that mutations in CAPN3, whose gene product is specifically expressed in skeletal muscle, have been associated with susceptibility to another tissue-specific eosinophilic disorder (eosinophilic myositis) [41] [42] [43] [44] [45] [46] . Although we do not yet know the molecular steps that link calpainopathy to eosinophilic responses, it is notable that CAPN14 belongs to the classical calpain subfamily that comprises one of the major proteolytic systems that mediate protein cleavage (in addition to the proteasome, lysosome and caspase systems) 47 . Classical calpains are calcium-regulatory proteases, and their substrates include structural proteins, signaling molecules, transcription factors 48, 49 and the inflammatory mediators that are germane for allergic responses 50, 51 , such as STAT6 (signal transducer and activator of transcription 6) and IL-33, the latter of which shows some association with EoE ( Supplementary Fig. 7 and Supplementary Table 2) . On the basis of the collective data, we propose a model that links the interplay of allergic sensitization with an EoE-specific, IL-13-inducible esophageal response involving CAPN14.
MEthods
Methods and any associated references are available in the online version of the paper.
Accession codes. The genotyping data from this study have been submitted to the database of Genotypes and Phenotypes (dbGaP) under accession phs000494.v1.p1. The expression data from this study have been submitted to the NCBI Gene Expression Omnibus (GEO) database under accession GSE58640. Funding for this project was provided by the US NIH, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Heart, Lung, and Blood Institute (NHLBI) and National Human Genome Research Institute (NHGRI) (U19 AI066738, U01 HG006828, U01 HG006828-S1, U01 HG006828-S2, U01 AI066560, R37 AI024717, P01 AI083194, T32 HL7752-19, K23 AI099083 and P01 AR049084). The CoFAR arm of the study was supported by US NIH grant U19 AI066738 from NIAID and NIDDK. The project was also supported by several grants from the National Center for Research Resources (NCRR), a component of the US NIH: UL1 TR001082 (National Jewish), UL1 TR-000067 (Mount Sinai), UL1 TR-000039 (Arkansas), UL1 TR-000083 (University of North Carolina) and UL1 TR-000424 (Johns Hopkins). Support was also received from the US Department of Veteran Affairs (IMMA 9) and the US Department of Defense (PR094002). This research was supported in part by the Cincinnati Children's Research Foundation and its Cincinnati Genomic Control Cohort. Other support was derived from the Campaign Urging Research for Eosinophilic Diseases (CURED), the Buckeye Foundation, the Food Allergy Research Education (FARE) Foundation and the Foundation of the American College of Allergy, Asthma and Immunology. The paper's contents are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or NIH. We also thank S. Hottinger for editorial assistance.
oNLINE MEthods
Genotyping. Genotyping was performed on the Illumina OMNI-5 and OMNI-2.5 genotyping arrays using Infinium2 chemistry. Genotypes were called using the Gentrain2 algorithm in Illumina Genome Studio software. A summary of the genotyping and analytical pipeline is given in Supplementary Figure 10. Subjects. The study was approved by the institutional review boards at CCHMC and all participating sites that were part of the US NIH CoFAR EoE cohort (Mount Sinai Medical Center, University of North Carolina, Johns Hopkins University, University of Colorado Health Center/National Jewish Research Center and Arkansas Children's Hospital). Parental informed consent was obtained from all participants in this study for the purpose of DNA collection and genotyping. Cases were confirmed by a physician to fulfill the diagnostic criteria for EoE. EoE is defined by a peak eosinophil count of ≥15 eosinophils/high-power field in esophageal biopsy sections; 30% of CCHMC and 51% of CoFAR cases had proton pump inhibitor (PPI) therapy before diagnostic endoscopy. Control subjects (without EoE) included the self-reported Caucasian subjects in the Cincinnati Genomic Control Cohort CCHMC (n = 831; age range of 2-18 years) 54 and an external control cohort (without EoE) acquired from a database of Genotypes and Phenotypes (dbGaP) University of Michigan study (n = 8,580). In the CCHMC and CoFAR cohorts, 73% and 62% of EoE cases were male, respectively, and EoE cases had an age range of 2-52 years. The external control cohort was collected through an aging and retirement study; subjects in this cohort were older than the cases at the time of DNA collection. The subjects in the external control cohort were randomly assigned to the CCHMC or CoFAR analysis with the goal of an equivalent case/control ratio in each cohort.
Population stratification. Genome-wide data were used to infer the top six principal components of genetic variation and correct for possible population stratification using EIGENSOFT. All local cases and controls were selfidentified as having European ancestry, and principal-component analysis was used to exclude all subjects (n = 271) who segregated more than 4 s.d. outside of the mean of the first 4 principal components. Specifically, we removed 34 genetic outliers from 736 EoE cases, 13 outliers from 235 CoFAR cases, 71 outliers from 831 CCHMC controls and 166 outliers from 8,652 dbGaP University of Michigan controls. The resulting genomic inflation factor was 1.001 for a set of ancestry-informative markers not including the associated loci. The genome-wide genomic inflation factors seen in our study for the CCHMC and CoFAR cohorts were 1.04 and 1.05, respectively.
Genotyping quality control. To confirm accurate genotyping and sample identification, we performed an identity-by-state analysis on a subset of 10,732 SNPs that were genotyped on both the Illumina OMNI-5 array and the previous GWAS platform (Illumina 550) 9 and found 99.998% concordance for the 134 samples that were genotyped on both platforms. Genome-wide genotyping data were deposited into dbGaP (phs000494.v1.p1). Of the original 4,301,332 markers on the OMNI-5 array, 2,512,766 were derived from rare variants (MAF < 1%). Notably, 87,539 markers had a suboptimal call rate (for example, <96%), and 44,246 were not in Hardy-Weinberg equilibrium in the controls (P < 1 × 10 −4 ). We assessed the 10,000 most significant variants in Genome Studio projects that included the locally genotyped cases and controls and the external controls from dbGaP; upon visual inspection, 124 of these SNPs did not cluster properly and were removed from further analysis. rs8041227 reached genomewide significance; however, no other SNPs around this variant in the data set were strongly associated. The Genome Studio cluster plot of this particular SNP is given in Supplementary Figure 11 . External controls were genotyped on the OMNI-2.5 array, and overlapping variants that passed the quality measures described above in both data sets were analyzed. We controlled for the presence of potential batch effects in the analysis of the CoFAR samples by removing SNPs that exhibited outlier fluorescence associated with deviation between plates (P < 1 × 10 −4 ), per the manufacturer's recommendation. The final genotyping rate for all SNPs was 99.7%. After applying the above filters, we used genotypes from 1,468,075 autosomal SNPs in a CCHMC cohort of 435 cases and 716 well-phenotyped local controls from CCHMC and 5,776 controls from the dbGaP study and a CoFAR cohort of 222 cases from the US NIH CoFAR EoE cohort and 2,804 controls from the University of Michigan Health and Retirement System (obtained from dbGaP) (Supplementary Table 1) .
Association and linkage disequilibrium analysis. After removing genetic outliers, we performed logistic regression to calculate P values and OR estimates for each SNP using PLINK 55 with sex as a covariate. For some analyses, atopy and the most significant SNP in the region were also used as covariates. For analyses that used atopy as a covariate, only subjects with known atopic status (EoE cases and local Cincinnati controls) were included. For cases, atopy was defined by a physician-documented history of positive skin-prick test results, allergic rhinitis, allergic dermatitis/eczema, asthma or food allergy. The prevalence of atopy for the local CCHMC and CoFAR EoE cohorts was 96.2% and 91.3%, respectively. For the Cincinnati Genomic Control Cohort, atopy was defined by a parent-reported history of allergic rhinitis, eczema, asthma or food allergy; the atopy prevalence of this cohort was 28.6%. LocusZoom 56 and R were used to map the associated loci in the context of chromosomal recombination and nearby genes.
Imputation to the 1000 Genomes Project reference panel. To detect associated variants that were not directly genotyped, we imputed highly associated regions with IMPUTE2 and used a composite imputation reference panel of integrated haplotypes from the 1000 Genomes Project sequence data freezes from March 2012 produced using the SHAPEIT2 program 17, 18 . Imputed genotypes were required to meet or exceed a probability threshold of 0.9, an information measure of >0.4 and the quality control criteria described for the genotyped markers.
Expression analysis. Quantitative RT-PCR analysis was performed on cDNA synthesized from distal esophageal biopsy RNA. EoE biopsies showed active disease pathology at the time they were taken, and all cases reported no glucocorticoid treatment at the time of biopsy, except for the analysis of gene expression as a function of disease activity in which remission was defined after glucocorticoid therapy. Statistical testing for mRNA expression normalized to the levels of GAPDH (encoding glyceraldehyde 3-phosphate dehydrogenase) or HPRT1 (encoding hypoxanthine phosphoribosyltransferase 1) was performed by Mann-Whitney U test using GraphPad Prism software.
Expression microarray analysis. For each case, one distal esophageal mucosal biopsy sample was immersed in RNAlater RNA stabilization reagent (Qiagen) and stored at 4 °C for less than 15 d. Total RNA was extracted using the RNeasy Mini kit (Qiagen) according to the manufacturer's recommendations. Hybridization to DNA microarrays was performed by the Microarray Core at CCHMC, as previously reported 13, 57 . The genome-wide human Affymetrix U133 Plus 2.0 GeneChip was used, and the relative expression of gene transcript levels were determined using algorithms in the Microarray Analysis Suite and GeneSpring software (Silicon Genetics).
RNA sequencing. Esophageal biopsy RNA was isolated from EoE cases with active disease and from unaffected controls as previously described 13, 38 . RNAseq acquiring 10 million mappable 100-bp reads from paired-end libraries was performed at the Genetic Variation and Gene Discovery Core Facility at CCHMC. Data were aligned to the GrCh37 build of the human genome using Ensembl 58 annotations as a guide for TopHat 59 . Expression analysis was performed using Cufflinks 60 . Data were visualized using the Integrative Genomics Viewer (Broad Institute). Enrichment analysis was performed using permutation testing that randomly selected SNPs from the chip, identified the nearest gene and assessed the number of genes expressed in the esophagus. Only 10 permutations out of 100,000 total permutations had more than or equal to 99 genes expressed in the esophagus.
Electrophoretic mobility shift assays. Pairs of single-stranded 5′ IRDye infrared dye-labeled and unlabeled oligonucleotides (obtained from IDT, Inc.) were annealed to generate double-stranded probes. We incubated 25-50 fmoles of labeled probe with 8 or 10 µg of nuclear extract prepared from the human esophageal cell line TE-7 (tested for mycoplasma infection), 6 µg of poly(deoxyinosinic-doxycytidylic) acid and 1 µl of salmon sperm provided along with the buffers and protocols supplied with the Odyssey Infrared EMSA kit (LI-COR Biosciences). Binding reactions were analyzed using electrophoresis on 6% Tris-borate-EDTA polyacrylamide gels and detected by an infrared npg
